🧪
hypothesis

plasma LPS-binding protein separates causal from compensatory states in: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegenerat

Hypothesis

plasma LPS-binding protein separates causal from compensatory states in: How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegenerat

A longitudinal biomarker panel centered on plasma LPS-binding protein can distinguish harmful mechanisms from protective adaptation.
🧬 plasma LPS-binding protein🩺 neurodegeneration🎯 Composite 35%💱 $0.54▼4.4%active
EvidencePending (0%)📖 6 cit🗣 2 debates 6 support 1 oppose
✓ All Quality Gates Passed
🏆 ChallengeValidate plasma LPS-binding protein as causal biomarker for gut-brain inflammati$400 →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite35%

🧪 Overview

A longitudinal biomarker panel centered on plasma LPS-binding protein can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma LPS-binding protein before and after TLR4 antagonism in stratified models.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Gut Dysbiosis<br/>SCFA-Producing Bacteria Loss"]
    B["Intestinal Permeability<br/>Leaky Gut Endotoxemia"]
    C["LPS Translocation<br/>Portal and Systemic Circulation"]
    D["TLR4 Activation<br/>MD-2 Coreceptor Complex"]
    E["MyD88 Signaling<br/>NF-kappaB and MAPK Cascade"]
    F["Peripheral Cytokine Storm<br/>IL-1beta and TNF Secretion"]
    G["Microglial Priming<br/>Brain Resident Immune Activation"]
    H["Neurodegeneration<br/>Synapse Loss and Tau Pathology"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    G --> H
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix5 supports1 contradicts
Supports
TLR4-dependent neuroinflammation mediates LPS-driven food-reward alterations during high-fat exposure.
J Neuroinflammation2024PMID:39580436medium
Supports
Early glycolytic reprogramming controls microglial inflammatory activation.
J Neuroinflammation2021PMID:34107997medium
Supports
Ferulic acid alleviates sciatica by inhibiting neuroinflammation and promoting nerve repair via the TLR4/NF-κB pathway.
CNS Neurosci Ther2023PMID:36601662medium
Supports
Gastrodin regulates the TLR4/TRAF6/NF-κB pathway to reduce neuroinflammation and microglial activation in an AD model.
Phytomedicine2024PMID:38552431medium
Supports
Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β.
Front Immunol2023PMID:37435081medium
Contradicts
causal direction requires longitudinal perturbation
skeptic_round
📖 Linked Papers (8)Export BibTeX ↗
Gastrodin regulates the TLR4/TRAF6/NF-κB pathway to reduce neuroinflammation and microglial activation in an AD model.
Phytomedicine : international journal of phytotherapy and phytopharmacology (2024) · PubMed:38552431 ↗
No figures
Gastrodin regulates the TLR4/TRAF6/NF-κB pathway to reduce neuroinflammation and microglial activation in an AD model.
Phytomedicine : international journal of phytotherapy and phytopharmacology (2024) · PubMed:38552431 ↗
No figures
Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β.
Frontiers in immunology (2023) · PubMed:37435081 ↗
No figures
Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β.
Frontiers in immunology (2023) · PubMed:37435081 ↗
No figures
Ferulic acid alleviates sciatica by inhibiting neuroinflammation and promoting nerve repair via the TLR4/NF-κB pathway.
CNS neuroscience & therapeutics (2023) · PubMed:36601662 ↗
No figures
Ferulic acid alleviates sciatica by inhibiting neuroinflammation and promoting nerve repair via the TLR4/NF-κB pathway.
CNS neuroscience & therapeutics (2023) · PubMed:36601662 ↗
No figures
Early glycolytic reprogramming controls microglial inflammatory activation.
Journal of neuroinflammation (2021) · PubMed:34107997 ↗
No figures
Early glycolytic reprogramming controls microglial inflammatory activation.
Journal of neuroinflammation (2021) · PubMed:34107997 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — PLASMA

No curated PDB or AlphaFold mapping for PLASMA yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for plasma LPS-binding protein →

No DepMap CRISPR Chronos data found for plasma LPS-binding protein.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.8%
Volatility
High
0.1687
Events (7d)
3
Price History
▼4.4%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF plasma LPS-binding protein separates causal dysbiosis from compensation, THEN baseline LBP in high-dysbiosis participants will predict >=20% faster rise in plasma GFAP or NfL over 18 months.Top-tertile LBP among dysbiotic participants predicts >=20% higher annual GFAP/NfL slope than bottom tertile.— no observation —pending0.58
IF LBP marks harmful SCFA-depletion states, THEN restoring butyrate-producing taxa will lower plasma LBP by >=15% and microglial activation PET signal by >=10% within 12 weeks.Butyrate-restoration intervention reduces LBP >=15% and TSPO-PET or equivalent neuroinflammation marker >=10%.— no observation —pending0.50
🔮 Falsifiable Predictions (2)
pendingconf 58%
IF plasma LPS-binding protein separates causal dysbiosis from compensation, THEN baseline LBP in high-dysbiosis participants will predict >=20% faster rise in plasma GFAP or NfL over 18 months.
Predicted outcome: Top-tertile LBP among dysbiotic participants predicts >=20% higher annual GFAP/NfL slope than bottom tertile.
Falsification: LBP tertiles differ by <5% in GFAP/NfL slope or association disappears after CRP/metabolic adjustment.
pendingconf 50%
IF LBP marks harmful SCFA-depletion states, THEN restoring butyrate-producing taxa will lower plasma LBP by >=15% and microglial activation PET signal by >=10% within 12 weeks.
Predicted outcome: Butyrate-restoration intervention reduces LBP >=15% and TSPO-PET or equivalent neuroinflammation marker >=10%.
Falsification: LBP falls <5% or neuroinflammation marker does not change despite verified SCFA increase.
View on SciDEX ↗